secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274220
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026
--------------------------------------------------------------------------------

- Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.
- R&D expenses $49.7M, up from $30.1M, driven by Phase 3 ARCHER II trial and global GBS regulatory filings.
- Cash and equivalents $188.7M as of Sep 30, 2025; operations funded into late Q1 2027 through key milestones.
- Tanruprubart (ANX005) GBS MAA submission on track for Jan 2026; FDA discussions on BLA generalizability package ongoing.
- Vonaprument (ANX007) Phase 3 ARCHER II trial enrolled 659 GA patients; topline data expected second half 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312525274220/0001193125-25-274220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312525274220/annx-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer